Rapid Micro Biosystems (RPID) to Be Acquired for $0.75 per Share in Cash
Merck KGaA agreed to acquire Rapid Micro Biosystems (RPID) for $0.75 per share in cash. The deal is expected to close in December 2026, pending regulatory approval and other conditions.
How this was made

The 30-second read
Why it matters
For RPID, the key tradable variable becomes the probability-weighted path to closing versus deal-break risk, with the offer price serving as a reference point for valuation and spread trading.
Market read
A definitive, all-cash acquisition agreement with a specific per-share price typically drives immediate repricing of the target and creates a spread-trading window until tender and closing conditions are satisfied.
What to watch
Traders should monitor tender-offer uptake, regulatory/antitrust review timing (if applicable), and any changes to the minimum tender condition that could delay or derail closing.
Background
The piece describes a definitive acquisition agreement, not a completed transaction, and notes closing is expected in December 2026 subject to tender and other customary conditions.
Ticker impact
Rapid Micro Biosystems agreed to be acquired by Merck KGaA for $0.75 per share in an all-cash deal, with December 2026 closing conditions.
Likely upward pressure toward the stated $0.75 offer as the market prices deal completion odds, with pullbacks on any tender/condition risk.
The article discloses a definitive acquisition agreement and a specific per-share cash price, which typically drives a spread convergence to the offer while completion remains conditional.
Market effects
Signals continued consolidation in life sciences tools/bioprocessing, potentially affecting deal expectations for nearby small-cap biotech/biotech-instrument names.
Limited direct regional spillover beyond US small-cap M&A sentiment.
Cross-border pharma/biotech M&A tone may influence European and US small-cap deal spreads.
Counterpoint
The stated cash price does not guarantee completion; any failure of tender minimums or other customary conditions can widen the spread and pressure the stock.
Key entities
- companyRapid Micro Biosystems
Target company being acquired for $0.75 per share in an all-cash transaction.
- companyMerck KGaA
Acquirer agreeing to purchase all outstanding shares of Rapid Micro Biosystems.
